To verify the universality and functional consequence of PTEN-SCD co-deletion events in cancers outside the central nervous system, we turned to melanoma since PTEN is deleted in ~57% and ~38% of B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutant and BRAF wild-type (WT) melanoma, respectively. The gene discussed is MARK2; the disease is cancer.